RecruitingPhase 3NCT06290128

A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work

A Phase 3, Double-blind, Placebo-controlled Study Evaluating Efficacy and Safety of Riliprubart in Participants With Refractory Chronic Inflammatory Demyelinating Polyneuropathy

Sponsor

Sanofi

Enrollment

140 participants

Start Date

Jul 12, 2024

Study Type

INTERVENTIONAL

Conditions

Chronic Inflammatory Demyelinating Polyradiculoneuropathy Polyneuropathy, Inflammatory Demyelinating, Chronic

Summary

The purpose of the study is to evaluate efficacy of riliprubart compared to placebo in adult participants with CIDP whose disease is refractory to standard of care. The study duration will be for a maximum of 111 weeks including screening, treatment phases, and follow-up.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Placebo, a drug called Placebo, and others for people with chronic inflammatory demyelinating polyradiculoneuropathy and polyneuropathy, inflammatory demyelinating, chronic. The study is currently recruiting participants at 131 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGRiliprubart

Pharmaceutical form: Solution Route of administration: IV Infusion

DRUGPlacebo

Pharmaceutical form: Solution Route of administration: IV Infusion

DRUGRiliprubart

Pharmaceutical form: Solution Route of administration: SC Injection

DRUGPlacebo

Pharmaceutical form: Solution Route of administration: SC Injection

Locations(131)

Alabama Neurology Associates- Site Number : 8400019

Homewood, Alabama, United States

USC Norris Comprehensive Cancer Center- Site Number : 8400002

Los Angeles, California, United States

University of California Irvine - Manchester Pavilion- Site Number : 8400007

Orange, California, United States

IMMUNOe International Research Centers - Centennial- Site Number : 8400049

Centennial, Colorado, United States

Yale University School of Medicine- Site Number : 8400018

New Haven, Connecticut, United States

Nova Clinical Research - Bradenton- Site Number : 8400044

Bradenton, Florida, United States

Design Neuroscience Center- Site Number : 8400053

Miami Lakes, Florida, United States

NorthShore University Health System - Glenbrook Hospital- Site Number : 8400024

Glenview, Illinois, United States

University of Kansas Medical Center- Site Number : 8400010

Kansas City, Kansas, United States

NeuroMedical Clinic of Central Louisiana- Site Number : 8400031

Alexandria, Louisiana, United States

Ochsner Medical Center - Jefferson Highway- Site Number : 8400030

New Orleans, Louisiana, United States

Johns Hopkins Hospital- Site Number : 8400015

Baltimore, Maryland, United States

Massachusetts General Hospital- Site Number : 8400009

Boston, Massachusetts, United States

Henry Ford Hospital- Site Number : 8400025

Detroit, Michigan, United States

Michigan State University- Site Number : 8400038

East Lansing, Michigan, United States

Washington University School of Medicine - Siteman Cancer Center- Site Number : 8400037

St Louis, Missouri, United States

Profound Research- Site Number : 8400052

Las Vegas, Nevada, United States

Hospital for Special Surgery- Site Number : 8400041

New York, New York, United States

Columbia University Irving Medical Center- Site Number : 8400003

New York, New York, United States

Raleigh Neurology Associates- Site Number : 8400043

Raleigh, North Carolina, United States

University of Cincinnati Medical Center- Site Number : 8400020

Cincinnati, Ohio, United States

University Hospitals Cleveland Medical Center- Site Number : 8400033

Cleveland, Ohio, United States

Penn State Health Milton South Hershey Medical Center- Site Number : 8400042

Hershey, Pennsylvania, United States

Penn Medicine: University of Pennsylvania Health System- Site Number : 8400022

Philadelphia, Pennsylvania, United States

Austin Neuromuscular Center- Site Number : 8400040

Austin, Texas, United States

UTHealth - The University of Texas Health Sciences Center at Houston- Site Number : 8400050

Houston, Texas, United States

University of Vermont Medical Center- Site Number : 8400012

Burlington, Vermont, United States

University of Virginia- Site Number : 8400023

Charlottesville, Virginia, United States

Investigational Site Number : 0320001

Buenos Aires, Argentina

Investigational Site Number : 0320002

Buenos Aires, Argentina

Investigational Site Number : 0320003

Buenos Aires, Argentina

Investigational Site Number : 0560001

Leuven, Belgium

Centro de Diagnostico e Pesquisa da Osteoporose do Espirito Santo- Site Number : 0760012

Vitória, Espírito Santo, Brazil

Hospital Sao Rafael- Site Number : 0760011

Salvador, Estado de Bahia, Brazil

Freire Pesquisa Clínica - Belo Horizonte - Rua Piauí- Site Number : 0760016

Belo Horizonte, Minas Gerais, Brazil

Hospital Moinhos de Vento- Site Number : 0760003

Porto Alegre, Rio Grande do Sul, Brazil

Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto- Site Number : 0760007

Ribeirão Preto, São Paulo, Brazil

PSEG Centro de Pesquisa Clínica- Site Number : 0760009

São Paulo, Brazil

Investigational Site Number : 1000002

Blagoevgrad, Bulgaria

Investigational Site Number : 1000001

Pleven, Bulgaria

Investigational Site Number : 1240001

Québec, Quebec, Canada

Investigational Site Number : 1520003

Lo Barnechea, Reg Metropolitana de Santiago, Chile

Investigational Site Number : 1520002

Santiago, Reg Metropolitana de Santiago, Chile

Investigational Site Number : 1520001

Santiago, Reg Metropolitana de Santiago, Chile

Investigational Site Number : 1560013

Beijing, China

Investigational Site Number : 1560010

Beijing, China

Investigational Site Number : 1560005

Beijing, China

Investigational Site Number : 1560016

Beijing, China

Investigational Site Number : 1560009

Changsha, China

Investigational Site Number : 1560011

Chengdu, China

Investigational Site Number : 1560002

Fuzhou, China

Investigational Site Number : 1560012

Guangzhou, China

Investigational Site Number : 1560007

Guangzhou, China

Investigational Site Number : 1560014

Hangzhou, China

Investigational Site Number : 1560008

Jinan, China

Investigational Site Number : 1560015

Nanchang, China

Investigational Site Number : 1560001

Shanghai, China

Investigational Site Number : 1560003

Wuhan, China

Investigational Site Number : 1560006

Wuhan, China

Investigational Site Number : 1560004

Xi'an, China

Investigational Site Number : 2030004

Brno, Czechia

Investigational Site Number : 2030003

Hradec Králové, Czechia

Investigational Site Number : 2030002

Pardubice, Czechia

Investigational Site Number : 2080002

Aarhus, Denmark

Investigational Site Number : 2080001

Copenhagen, Denmark

Investigational Site Number : 2500001

Le Kremlin-Bicêtre, France

Investigational Site Number : 2500003

Lille, France

Investigational Site Number : 2500002

Marseille, France

Investigational Site Number : 2500005

Montpellier, France

Investigational Site Number : 2500004

Paris, France

Investigational Site Number : 2760001

Bad Homburg, Germany

Investigational Site Number : 2760004

Berlin, Germany

Investigational Site Number : 2760007

Bochum, Germany

Investigational Site Number : 2760005

Essen, Germany

Investigational Site Number : 2760003

Giessen, Germany

Investigational Site Number : 2760006

Tübingen, Germany

Investigational Site Number : 3000002

Athens, Greece

Investigational Site Number : 3000003

Larissa, Greece

Investigational Site Number : 3000001

Thessaloniki, Greece

Investigational Site Number : 3800001

Milan, Milano, Italy

Investigational Site Number : 3800009

Rozzano, Milano, Italy

Investigational Site Number : 3800006

Rome, Roma, Italy

Investigational Site Number : 3800008

Rome, Roma, Italy

Investigational Site Number : 3800007

Messina, Italy

Investigational Site Number : 3800003

Palermo, Italy

Investigational Site Number : 3800005

Pavia, Italy

Investigational Site Number : 3800004

Pisa, Italy

Investigational Site Number : 3920006

Sayama, Osaka, Japan

Investigational Site Number : 3920005

Kawagoe, Saitama, Japan

Investigational Site Number : 3920014

Yaizu, Shizuoka, Japan

Investigational Site Number : 3920011

Bunkyo-Ku, Tokyo, Japan

Investigational Site Number : 3920008

Kodaira, Tokyo, Japan

Investigational Site Number : 3920001

Chiba, Japan

Investigational Site Number : 3920003

Fukuoka, Japan

Investigational Site Number : 3920009

Saga, Japan

Investigational Site Number : 3920013

Tokyo, Japan

Investigational Site Number : 4840003

Guadalajara, Jalisco, Mexico

Investigational Site Number : 4840005

Culiacán, Sinaloa, Mexico

Investigational Site Number : 4840002

Veracruz, Mexico

Investigational Site Number : 5280001

Amsterdam, Netherlands

Investigational Site Number : 5280002

Rotterdam, Netherlands

Investigational Site Number : 6160006

Krakow, Lesser Poland Voivodeship, Poland

Investigational Site Number : 6160002

Lublin, Lublin Voivodeship, Poland

Investigational Site Number : 6160003

Rzeszów, Podkarpackie Voivodeship, Poland

Investigational Site Number : 6200005

Coimbra, Portugal

Investigational Site Number : 6200004

Lisbon, Portugal

Investigational Site Number : 6200001

Lisbon, Portugal

Investigational Site Number : 6200003

Matosinhos Municipality, Portugal

Investigational Site Number : 4100003

Seoul, Seoul-teukbyeolsi, South Korea

Investigational Site Number : 4100002

Seoul, Seoul-teukbyeolsi, South Korea

Investigational Site Number : 4100001

Seoul, Seoul-teukbyeolsi, South Korea

Investigational Site Number : 7240012

Santiago de Compostela, A Coruña [La Coruña], Spain

Investigational Site Number : 7240008

Barcelona, Barcelona [Barcelona], Spain

Investigational Site Number : 7240007

Bilbao, Basque Country, Spain

Investigational Site Number : 7240001

Barcelona, Catalunya [Cataluña], Spain

Investigational Site Number : 7240006

Majadahonda, Madrid, Spain

Investigational Site Number : 7240003

Pamplona, Navarre, Spain

Investigational Site Number : 7240005

Oviedo, Principality of Asturias, Spain

Investigational Site Number : 7240009

Sabadell, Spain

Investigational Site Number : 7240010

Santa Cruz de Tenerife, Spain

Investigational Site Number : 7240002

Valencia, Spain

Investigational Site Number : 7520001

Stockholm, Sweden

Investigational Site Number : 1580003

Kaohsiung City, Taiwan

Investigational Site Number : 1580001

Taipei, Taiwan

Investigational Site Number : 1580002

Taipei, Taiwan

Investigational Site Number : 7920006

Ankara, Turkey (Türkiye)

Investigational Site Number : 7920007

Ankara, Turkey (Türkiye)

Investigational Site Number : 7920002

Bursa, Turkey (Türkiye)

Investigational Site Number : 7920001

Istanbul, Turkey (Türkiye)

Investigational Site Number : 7920004

Istanbul, Turkey (Türkiye)

Investigational Site Number : 7920003

Konya, Turkey (Türkiye)

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06290128

Related Trials

A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP

NCT0709163071 locations

Biomarkers in Autoimmune Disease of Nervous System

NCT065020151 location

Real-world Study of Treatment Outcomes in Chronic Inflammatory Demyelinating Polyneuropathy/Polyradiculoneuropathy (CIDP)

NCT069689751 location

Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study

NCT0726442623 locations

Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/B Cell Maturation Antigen （CD19/BCMA） in Patients With r/r Neurological Autoimmune Diseases

NCT069391661 location